ATE445641T1 - Glucagon ähnliche peptide-2 und ihre therapeutische verwendung - Google Patents

Glucagon ähnliche peptide-2 und ihre therapeutische verwendung

Info

Publication number: ATE445641T1
Authority: AT; Austria
Prior art keywords: glucagon; peptide; therapeutic use; bowel; analogs
Prior art date: 1995-04-14

Application number

AT96908973T

Other languages

English (en)

Inventor

Daniel Drucker

Original Assignee

Ontario Inc 1149336

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-14

Filing date

1996-04-12

Publication date

2009-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23675346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445641(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-12 Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE445641T1 publication Critical patent/ATE445641T1/de

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 3
102100040918 Pro-glucagon Human genes 0.000 title abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 3
230000001225 therapeutic effect Effects 0.000 title abstract 2
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000012010 growth Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
210000004153 islets of langerhan Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000008467 tissue growth Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Obesity (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Emergency Medicine (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)

AT96908973T 1995-04-14 1996-04-12 Glucagon ähnliche peptide-2 und ihre therapeutische verwendung ATE445641T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/422,540 US5990077A (en)	1995-04-14	1995-04-14	Glucagon-like peptide-2 and its therapeutic use
PCT/CA1996/000232 WO1996032414A1 (en)	1995-04-14	1996-04-12	Glucagon-like peptide-2 and its therapeutic use

Publications (1)

Publication Number	Publication Date
ATE445641T1 true ATE445641T1 (de)	2009-10-15

Family

ID=23675346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96908973T ATE445641T1 (de)	1995-04-14	1996-04-12	Glucagon ähnliche peptide-2 und ihre therapeutische verwendung

Country Status (13)

Country	Link
US (1)	US5990077A (de)
EP (4)	EP2277909A1 (de)
JP (3)	JPH11505521A (de)
CN (2)	CN101254300B (de)
AT (1)	ATE445641T1 (de)
AU (1)	AU720493B2 (de)
CA (1)	CA2218225C (de)
CY (1)	CY2615B2 (de)
DE (1)	DE69638057D1 (de)
DK (1)	DK0830377T4 (de)
ES (1)	ES2334864T5 (de)
PT (1)	PT830377E (de)
WO (1)	WO1996032414A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
DE69740176D1 (de) *	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU753771B2 (en) *	1996-04-12	2002-10-31	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
EP1231219B1 (de)	1996-04-12	2010-08-25	1149336 Ontario Inc.	Dem Glukagon ähnliches Peptid-2
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
EP0929576A1 (de) *	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivate
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
DE69737561T2 (de) *	1996-12-13	2008-03-06	Nps Allelix Corp., Toronto	Klonierte rezeptoren des glukagon-ähnlichen peptids-2
US8592553B2 (en)	1996-12-13	2013-11-26	Nps Pharmaceuticals, Inc.	Cloned glucagon-like peptide-2 receptors
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
CA2289652C (en) *	1997-05-16	2012-02-28	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
EP1060192A2 (de) *	1998-02-27	2000-12-20	Novo Nordisk A/S	Glp-2 derivate mit einem helixgehalt über 25%, die partiell strukturierte mizellenartige aggregate bilden
EP2348044A1 (de)	1999-03-15	2011-07-27	Novo Nordisk A/S	Ionenaustauschchromatographie von GLP-1, Analoga und Derivate davon
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
EP1970072A1 (de) *	2000-09-18	2008-09-17	Sanos Bioscience A/S	Verwendung von GLP-2-Peptiden zur Behandlung von Hyperparathyreodismus
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
IL155812A0 (en) *	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
US7374930B2 (en) *	2002-05-21	2008-05-20	Expression Genetics, Inc.	GLP-1 gene delivery for the treatment of type 2 diabetes
US20040038864A1 (en) *	2002-06-27	2004-02-26	Per Balschmidt	Use of dimethyl sulfone as isotonicity agent
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
WO2004035624A2 (en) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
DE602004031927D1 (de)	2003-02-04	2011-05-05	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
BRPI0413644A (pt)	2003-08-21	2006-10-17	Novo Nordisk As	métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
WO2005082404A2 (en) *	2004-02-27	2005-09-09	Novo Nordisk A/S	Glp-2 derivatives modified by lipophilic substituents
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
UA95235C2 (en) †	2005-05-04	2011-07-25	Зииланд Фарма А/С	Glucagon-like-peptide-2 (glp-2) analogues
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (de)	2006-02-22	2015-07-10	Mannkind Corp
CN101573376B (zh)	2006-11-08	2013-11-06	西兰制药公司	选择性胰高血糖素样肽-2（glp-2）类似物
JP2011500850A (ja) *	2007-10-24	2011-01-06	マンカインドコーポレイション	Ｇｌｐ−１による副作用を防止する方法
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US20100081622A1 (en) *	2008-09-29	2010-04-01	Sanos Bioscience A/S	Reduction of parathyroid hormone levels
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
CN101824087A (zh) *	2009-03-05	2010-09-08	连云港恒邦医药科技有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
EP2311486A1 (de) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de)	2009-10-23	2011-04-27	Ferring B.V.	GLP-2-Peptid-Agonisten
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6206972B2 (ja)	2011-09-12	2017-10-04	アムニクスオペレーティングインコーポレイテッド	グルカゴン様ペプチド−２組成物およびその作製法および使用法
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
JP6355563B2 (ja)	2012-02-27	2018-07-11	アムニクスオペレーティングインコーポレイテッド	Ｘｔｅｎ共役組成物およびそれを製造する方法
CN104540850B (zh)	2012-05-03	2018-05-18	西兰制药公司	胰高血糖素样肽2(glp-2)类似物
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
WO2014145718A2 (en)	2013-03-15	2014-09-18	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
CN104055757B (zh) *	2014-07-09	2016-03-16	中国人民解放军第三军医大学第三附属医院	胍丁胺用于制备治疗细菌毒素所致小肠结构损害药物的用途
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
EP3551651B1 (de)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylierte glp-1/glp-2 duale agoniste
IL299864B2 (en)	2017-06-16	2024-06-01	Zealand Pharma As	Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
KR20220150270A (ko)	2019-10-07	2022-11-10	칼리오페, 인크.	Gpr119 효능제
TW202140440A (zh)	2020-02-28	2021-11-01	美商克力歐普股份有限公司	Gpr40激動劑

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en)	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1575343A (en)	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4529561A (en)	1978-03-24	1985-07-16	The Regents Of The University Of California	Method for producing liposomes in selected size range
GB2046092B (en)	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en)	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4725442A (en)	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en)	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
JP2583257B2 (ja) *	1986-05-05	1997-02-19	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン向性ホルモン
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5009956A (en)	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
US4927637A (en)	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
ATE164852T1 (de) *	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
EP0969016A2 (de) *	1992-06-15	2000-01-05	Scios Inc.	Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
JP2961045B2 (ja) *	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
DE69740176D1 (de) *	1996-03-01	2011-05-26	Novo Nordisk As	Appetithemmendes Peptid, Zusammensetzung und Verwendung
EP1231219B1 (de) *	1996-04-12	2010-08-25	1149336 Ontario Inc.	Dem Glukagon ähnliches Peptid-2

1995
- 1995-04-14 US US08/422,540 patent/US5990077A/en not_active Expired - Lifetime
1996
- 1996-04-12 JP JP8530606A patent/JPH11505521A/ja not_active Withdrawn
- 1996-04-12 ES ES96908973T patent/ES2334864T5/es not_active Expired - Lifetime
- 1996-04-12 CA CA2218225A patent/CA2218225C/en not_active Expired - Lifetime
- 1996-04-12 AT AT96908973T patent/ATE445641T1/de active
- 1996-04-12 PT PT96908973T patent/PT830377E/pt unknown
- 1996-04-12 AU AU52658/96A patent/AU720493B2/en not_active Expired
- 1996-04-12 EP EP10012214A patent/EP2277909A1/de not_active Withdrawn
- 1996-04-12 CN CN2008100012906A patent/CN101254300B/zh not_active Expired - Lifetime
- 1996-04-12 DE DE69638057T patent/DE69638057D1/de not_active Expired - Lifetime
- 1996-04-12 WO PCT/CA1996/000232 patent/WO1996032414A1/en not_active Ceased
- 1996-04-12 EP EP08154372.0A patent/EP1988100B1/de not_active Expired - Lifetime
- 1996-04-12 EP EP96908973A patent/EP0830377B2/de not_active Expired - Lifetime
- 1996-04-12 DK DK96908973.9T patent/DK0830377T4/da active
- 1996-04-12 EP EP10012215A patent/EP2277530A1/de not_active Withdrawn
- 1996-04-12 CN CNB961946938A patent/CN100374461C/zh not_active Expired - Lifetime
2006
- 2006-07-05 JP JP2006185610A patent/JP4496183B2/ja not_active Expired - Lifetime
2010
- 2010-01-25 JP JP2010012787A patent/JP5281594B2/ja not_active Expired - Lifetime
2011
- 2011-04-15 CY CY1100004A patent/CY2615B2/xx unknown

Also Published As

Publication number	Publication date
CY2615B2 (en)	2012-01-25
JP5281594B2 (ja)	2013-09-04
AU5265896A (en)	1996-10-30
CA2218225A1 (en)	1996-10-17
EP1988100B1 (de)	2015-03-04
ES2334864T5 (es)	2013-04-08
DK0830377T4 (da)	2013-03-11
JP4496183B2 (ja)	2010-07-07
CN101254300B (zh)	2013-05-08
DE69638057D1 (de)	2009-11-26
CN1188485A (zh)	1998-07-22
JPH11505521A (ja)	1999-05-21
CA2218225C (en)	2014-09-23
MX9707949A (es)	1998-06-30
ES2334864T3 (es)	2010-03-16
JP2010159259A (ja)	2010-07-22
US5990077A (en)	1999-11-23
EP2277530A1 (de)	2011-01-26
EP2277909A1 (de)	2011-01-26
EP0830377B2 (de)	2012-12-12
EP1988100A1 (de)	2008-11-05
JP2006342172A (ja)	2006-12-21
CN101254300A (zh)	2008-09-03
DK0830377T3 (da)	2010-03-01
CN100374461C (zh)	2008-03-12
WO1996032414A1 (en)	1996-10-17
PT830377E (pt)	2010-01-19
EP0830377A1 (de)	1998-03-25
EP0830377B1 (de)	2009-10-14
AU720493B2 (en)	2000-06-01

Legal Events

Date

Code

Title

Description

2010-06-15

UEP

Publication of translation of european patent specification

Ref document number: 0830377

Country of ref document: EP

Publication	Publication Date	Title
ATE445641T1 (de)	2009-10-15	Glucagon ähnliche peptide-2 und ihre therapeutische verwendung
EP2218734A3 (de)	2010-10-13	Analoge des Glucagon ähnlichen Peptides-2
IL130931A0 (en)	2001-01-28	Small molecules useful in the treatment of inflammatory disease
NO962088L (no)	1996-05-22	Preparat for in vivo-produksjon av terapeutiske produkter
NO304793B1 (no)	1999-02-15	nor-gallesyrederivater, og anvendelse av dem for fremstilling av legemiddel
PL342078A1 (en)	2001-05-21	Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
ATE205086T1 (de)	2001-09-15	Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE338771T1 (de)	2006-09-15	Antagonisten des intestinotrophen glp-2 peptides
DK0506539T3 (da)	1997-12-01	heterocykliske alkylamider, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE69814394D1 (de)	2003-06-12	Verwendung von levobupivacain
FI964332A0 (fi)	1996-10-28	Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
FI972308A0 (fi)	1997-05-30	2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE69029231D1 (de)	1997-01-09	Indolderivate, ihre herstellung und diese enthaltendes arzneimittel zum verhindern und behandeln von nephritis
DE69228997D1 (de)	1999-05-27	Menschliche il-3-varianten
DE3879811D1 (de)	1993-05-06	Pharmazeutische zusammensetzung und ihre verwendung.
BG105275A (en)	2001-11-30	Tan-1057 derivatives
DE69630391D1 (de)	2003-11-20	Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
DE3481057D1 (de)	1990-02-22	2-sulfamoylbenzo(b)thiophen-derivate, ihre herstellung und pharmazeutische zubereitung zur behandlung von erhoehtem augeninnendruck.
DE69916488D1 (de)	2004-05-19	Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
EP0672052A1 (de)	1995-09-20	Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen.
DE59002899D1 (de)	1993-11-04	Aromatische carbonsaeureamide, ihre herstellung und verwendung fuer heilmittel.
AU3862997A (en)	1998-02-20	Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
ID20165A (id)	1998-10-15	Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
DK0703781T3 (da)	2000-10-02	Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
ATE112276T1 (de)	1994-10-15	Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.